Publication date: Jun 23, 2026
Cross-reactive antibodies against dengue virus are known to cause antibody-dependent enhancement (ADE) of infection or disease severity under specific conditions. In our previous study, we showed that primary immunization with the COVID-19 vaccine induces induces cross-reactive IgG causing ADE against dengue. In the present study, we investigated the influence of IgG Fc-glycosylation (analyzed by LC-MS/MS) on ADE mediated by cross-reactive IgG against dengue from IgG against SARS-CoV-2. We found a clear correlation between anti-DENV2 E IgG2 galactosylation and the ADE capacity of cross-reactive IgG against dengue in individuals vaccinated against COVID-19. IgG2 sialylation increased over time; however, it was not correlated with ADE capacity. This phenomenon was restricted to IgG2, whereas anti-DENV2 E IgG1 Fc-glycosylation remained stable after COVID-19 vaccination.
| Concepts | Keywords |
|---|---|
| Annually | Ade |
| Flaviviruses | Anti |
| Germany | Antibodies |
| Violin | Antibody |
| Copyright | |
| Cross | |
| Dengue | |
| Denv2 | |
| Doi | |
| Galactosylation | |
| Glycosylation | |
| Igg | |
| Igg2 | |
| Preprint | |
| Reactive |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | dengue |
| disease | MESH | infection |
| disease | MESH | COVID-19 |
| pathway | REACTOME | Translation |
| disease | MESH | viral infections |
| disease | MESH | severe dengue |
| pathway | KEGG | Viral replication |
| disease | MESH | PBS |
| drug | DRUGBANK | Human Serum Albumin |
| drug | DRUGBANK | Esomeprazole |
| disease | MESH | infectious diseases |
| pathway | REACTOME | Complement cascade |
| disease | MESH | Dis |
| disease | MESH | Aids |